Book a Meeting

Non-Fucosylated Anti-Human Sclerostin (Scl-Ab) Therapeutic Antibody (CAT#: BioBet-1308ZP) Datasheet

Target
Sclerostin
Isotype
IgG
Description
ADCC-Enhanced anti-Sclerostin (Scl-Ab) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Bone-related Diseases
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Sclerostin antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SOST
Full Name
sclerostin
Background
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
Alternative Names
SOST; sclerostin; CDD; VBCH; SOST1
Gene ID
50964
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with SOST include Sclerosteosis 1 and Craniodiaphyseal Dysplasia, Autosomal Dominant.
Related Pathways
Its related pathways are Signaling by GPCR and Signaling by Wnt.
Function
Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
Field of research
Developmental Biology antibody; Signaling Transduction antibody
Post-translational modifications
Glycosylation at Asn53 and Asn175
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
Scl-Ab
Host
Humanized
Species Reactivity
Human
Description
AMG 167 is a humanized monoclonal antibody that inhibits the action of sclerostin. AMG 167 is being developed for bone-related conditions.
Indication
Bone-related Diseases

Bone-related Diseases

Related Products

Highly Galactosylated Anti-Sclerostin (Romosozumab) Antibody (CAT#: BioBet-GA-012ZP)
Non-Fucosylated Anti-Human Sclerostin (AMG 167) Therapeutic Antibody (CAT#: BioBet-1307ZP)
Non-fucosylated Anti-Human Sclerostin (Romosozumab) Therapeutic Antibody (CAT#: BioBet-012ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany